FLOVENT
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
3/8 — Basic
FLOVENT by GSK is anti-inflammatory activity. First approved in 1996.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOVENT (fluticasone propionate) is a metered-dose inhaled corticosteroid approved in 1996 for asthma management. It works via potent glucocorticoid receptor binding (18× dexamethasone affinity) to reduce inflammation across multiple cell types and mediators involved in asthma pathogenesis. The drug exhibits high local anti-inflammatory activity with minimal systemic bioavailability (<1%), providing a favorable topical-to-systemic ratio.
LOE Approaching
As LOE approaches, the brand is transitioning from growth to maintenance phase; expect smaller commercial teams focused on generic defense and niche positioning.
Mechanism of Action
anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on FLOVENT at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.